FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897664706> ?p ?o ?g. }

• W2897664706 endingPage "2334" @default.
• W2897664706 startingPage "2325" @default.
• W2897664706 abstract "Insulin glargine 300 U/mL (Gla-300, Toujeo®) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland.The prospective, observational, open-label, multicenter study TOP-2 explored the effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on their previous basal insulin in Germany, Austria, and Switzerland. The primary endpoints were the percentages of patients achieving a fasting plasma glucose (FPG) of ≤ 6.1 mmol/L after 6 and 12 months. Secondary endpoints included changes in HbA1c, FPG, body weight, and insulin dose as well as hypoglycemia incidence and safety. Here we report the results for the Swiss patient cohort after 12 months of treatment with insulin glargine 300 U/mL.The 62 patients (33 men) had a mean age of 65 years, a mean diabetes duration of 14 years, a mean body mass index (BMI) of 31 kg/m2, and were mainly switched from Gla-100 (44%) to Gla-300. The most common concomitant oral anti-diabetes therapy was metformin (65%). The mean individual HbA1c target chosen by the investigators was 7.4%. After 12 months of therapy, Gla-300 significantly reduced mean HbA1c from 8.2% to 7.6% (p < 0.0001). Likewise, Gla-300 significantly reduced mean FPG from 9.1 mmol/L to 7.4 mmol/L (p < 0.0001). At study end, 32% of patients achieved FPG ≤ 6.1 mmol/L, 55% achieved FPG ≤ 7.2 mmol/L , and 57% achieved their individual HbA1c target. Gla-300 was uptitrated to a mean dose of 40 units per day. Symptomatic hypoglycemia incidence after 12 months was low at 9.7% and a rate of 0.23 events per patient year. Body weight remained stable and was not significantly altered during the study.Upon switching basaI insulin to Gla-300, overall glucose control significantly improved and glycemic targets were achieved with a low rate of hypoglycemia in T2D patients under real-world conditions in Switzerland.Sanofi-Aventis (Suisse) SA." @default.
• W2897664706 created "2018-10-26" @default.
• W2897664706 creator A5051239331 @default.
• W2897664706 creator A5068812195 @default.
• W2897664706 date "2018-10-09" @default.
• W2897664706 modified "2023-10-09" @default.
• W2897664706 title "Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland" @default.
• W2897664706 cites W1613501644 @default.
• W2897664706 cites W1726580060 @default.
• W2897664706 cites W1849264946 @default.
• W2897664706 cites W2065510740 @default.
• W2897664706 cites W2100633491 @default.
• W2897664706 cites W2105744242 @default.
• W2897664706 cites W2126781806 @default.
• W2897664706 cites W2172193326 @default.
• W2897664706 cites W2226954704 @default.
• W2897664706 cites W2294691063 @default.
• W2897664706 cites W2336512859 @default.
• W2897664706 cites W2388825372 @default.
• W2897664706 cites W2560688864 @default.
• W2897664706 cites W2743088090 @default.
• W2897664706 cites W2745170751 @default.
• W2897664706 cites W2751339385 @default.
• W2897664706 cites W2770468706 @default.
• W2897664706 cites W2777315381 @default.
• W2897664706 cites W2788236437 @default.
• W2897664706 cites W2793732091 @default.
• W2897664706 cites W2808801699 @default.
• W2897664706 cites W2808886095 @default.
• W2897664706 cites W2808992892 @default.
• W2897664706 cites W2887818979 @default.
• W2897664706 cites W4230570152 @default.
• W2897664706 cites W4292528167 @default.
• W2897664706 doi "https://doi.org/10.1007/s13300-018-0518-x" @default.
• W2897664706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6250621" @default.
• W2897664706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30302721" @default.
• W2897664706 hasPublicationYear "2018" @default.
• W2897664706 type Work @default.
• W2897664706 sameAs 2897664706 @default.
• W2897664706 citedByCount "10" @default.
• W2897664706 countsByYear W28976647062019 @default.
• W2897664706 countsByYear W28976647062020 @default.
• W2897664706 countsByYear W28976647062021 @default.
• W2897664706 countsByYear W28976647062023 @default.
• W2897664706 crossrefType "journal-article" @default.
• W2897664706 hasAuthorship W2897664706A5051239331 @default.
• W2897664706 hasAuthorship W2897664706A5068812195 @default.
• W2897664706 hasBestOaLocation W28976647061 @default.
• W2897664706 hasConcept C126322002 @default.
• W2897664706 hasConcept C134018914 @default.
• W2897664706 hasConcept C2775927303 @default.
• W2897664706 hasConcept C2777180221 @default.
• W2897664706 hasConcept C2779306644 @default.
• W2897664706 hasConcept C2779920387 @default.
• W2897664706 hasConcept C2780221984 @default.
• W2897664706 hasConcept C2780323712 @default.
• W2897664706 hasConcept C2780473172 @default.
• W2897664706 hasConcept C2780668416 @default.
• W2897664706 hasConcept C2780677441 @default.
• W2897664706 hasConcept C555293320 @default.
• W2897664706 hasConcept C71924100 @default.
• W2897664706 hasConceptScore W2897664706C126322002 @default.
• W2897664706 hasConceptScore W2897664706C134018914 @default.
• W2897664706 hasConceptScore W2897664706C2775927303 @default.
• W2897664706 hasConceptScore W2897664706C2777180221 @default.
• W2897664706 hasConceptScore W2897664706C2779306644 @default.
• W2897664706 hasConceptScore W2897664706C2779920387 @default.
• W2897664706 hasConceptScore W2897664706C2780221984 @default.
• W2897664706 hasConceptScore W2897664706C2780323712 @default.
• W2897664706 hasConceptScore W2897664706C2780473172 @default.
• W2897664706 hasConceptScore W2897664706C2780668416 @default.
• W2897664706 hasConceptScore W2897664706C2780677441 @default.
• W2897664706 hasConceptScore W2897664706C555293320 @default.
• W2897664706 hasConceptScore W2897664706C71924100 @default.
• W2897664706 hasIssue "6" @default.
• W2897664706 hasLocation W28976647061 @default.
• W2897664706 hasLocation W28976647062 @default.
• W2897664706 hasLocation W28976647063 @default.
• W2897664706 hasLocation W28976647064 @default.
• W2897664706 hasOpenAccess W2897664706 @default.
• W2897664706 hasPrimaryLocation W28976647061 @default.
• W2897664706 hasRelatedWork W1980381838 @default.
• W2897664706 hasRelatedWork W2068789151 @default.
• W2897664706 hasRelatedWork W2077148563 @default.
• W2897664706 hasRelatedWork W2323171412 @default.
• W2897664706 hasRelatedWork W2490309778 @default.
• W2897664706 hasRelatedWork W2577825165 @default.
• W2897664706 hasRelatedWork W2589876556 @default.
• W2897664706 hasRelatedWork W3197438476 @default.
• W2897664706 hasRelatedWork W4292539598 @default.
• W2897664706 hasRelatedWork W4323669241 @default.
• W2897664706 hasVolume "9" @default.
• W2897664706 isParatext "false" @default.
• W2897664706 isRetracted "false" @default.
• W2897664706 magId "2897664706" @default.
• W2897664706 workType "article" @default.